ArticleGland surgery2025
Recurrence after ablation of Bethesda IV thyroid nodule: report of two cases.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bethesda IV follicular neoplasms [2-25% of fine-needle aspiration (FNA) diagnoses] pose significant diagnostic challenges due to their malignant potential. Thermal ablation (TA) has emerged as a minimally invasive alternative to surgery, though its safety for follicular neoplasms remains controversial given cytology's inability to assess capsular/vascular invasion-the diagnostic gold standard. Case Description: This case report analyzes two patients with Bethesda IV nodules treated with microwave ablation (MWA). Case 1 involved a 26-year-old female with a 5.1 cm nodule undergoing two MWA sessions, while Case 2 featured a 12-year-old female with a 2.6 cm nodule receiving single-session MWA. Both cases deviated from guideline-recommended dual preoperative FNAs. Both patients developed recurrence: Case 1: progression of thyroid carcinoma within the ablation zone and metastatic papillary carcinoma in cervical lymph nodes were surgically confirmed two years post-ablation. Case 2: a recurrent cystic-solid nodule (1.8 cm) was detected adjacent to the ablation zone during 9-month post-procedural surveillance. Notably, neither recurrence displayed typical follicular carcinoma histology, suggesting ablation-induced diagnostic obscuration. Conclusions: These first-reported recurrence cases after TA for Bethesda IV nodules underscore critical limitations: violations of pre-ablation diagnostic protocols [dual FNA/core needle biopsy (CNB)] exacerbated malignancy risks, while TA-induced obscuration of histopathological evaluation delayed cancer diagnosis. Current guidelines appropriately exclude follicular neoplasms from TA indications, with surgical resection remaining the gold standard. TA should be restricted to validated research protocols pending establishment of robust risk-stratification criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.